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OBJECTIVES To examine the Framingham stroke risk profile (FSRP), the Cardiovascular 
Risk Factors, Aging and Dementia (CAIDE) risk score, and biomarkers of inflammation and 
oxidative stress for associations with cognitive decline using three different cohort studies of 
the very old. Also, to examine if incorporating these biomarkers with the risk scores can 
affect the association with cognitive decline. 
DESIGN Three longitudinal, population based cohort studies. 
SETTING Newcastle upon Tyne, UK, Leiden, The Netherlands and Lakes or Bay of Plenty 
District Health Board areas, New Zealand. 
PARTICIPANTS At baseline there were 616 participants in the Newcastle 85+ Study, 444 
participants in the Leiden 85-plus Study and 396 participants in the LiLACS NZ Study (non-
Māori population only) to analyse. 
MEASUREMENTS 1) FSRP, 2) CAIDE risk score, 3) oxi-inflammatory load: cumulative 
risk score of three blood biomarkers including homocysteine, interleukin-6 and C-reactive 
protein, representing levels of oxidative stress and inflammation and 4) FSRP incorporating 
the oxi-inflammatory load 5) CAIDE risk score incorporating the oxi-inflammatory load. The 
oxi-inflammatory load could only be calculated in the Newcastle 85+ Study and the Leiden 
85-plus Study. Baseline and prospective measures of global cognitive function (MMSE©) 
were available for all three datasets. Domain specific measures (attention, speed and memory) 
were available for the Newcastle 85+ Study and the Leiden 85-plus Study.  
RESULTS Meta-analysis of pooled results showed an increased risk of incident global 
cognitive impairment with higher FSRP (HR=1.46, 95%CI: 1.08 to 1.98), CAIDE (HR=1.53, 
95%CI: 1.09 to 2.14) scores and oxi-inflammatory load (HR=1.73, 95%CI: 1.04 to 2.88). 
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Adding the oxi-inflammatory load to the risk scores increased the hazard ratios for the FSRP 
(HR=1.65, 95% CI: 1.17 to 2.33) and the CAIDE model (HR=1.93 (1.39 to 2.67). 
CONCLUSION Incorporating the oxi-inflammatory load with cardiovascular risk scores may 
be useful for determining risk of future cognitive impairment in the very old. 
Key words: cardiovascular risk, biomarkers, cognitive function, dementia, cognitive decline 
5 
 
 
 
Risk factors for cardiovascular disease (CVD) and stroke such as hypertension and high 
cholesterol have been associated with cognitive decline and dementia.1 Many cardiovascular 
risk factors often co-occur, and risk prediction models have been developed to predict an 
individual’s risk of future CVD or stroke, such as the Framingham Stroke Risk Profile 
(FSRP).2 The Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score was 
specifically developed for the midlife population to predict future risk of dementia based on 
cardiovascular and lifestyle factors.3 Further, blood biomarkers, such as C-reactive protein, 
homocysteine and interleukin-6, are independent risk factors of CVD.4 
Previous longitudinal studies have suggested an association between cardiovascular risk 
models and cognitive decline, but these studies have been conducted midlife and younger old 
populations.5-12 This association has not yet been explored in the very old. Cardiovascular 
biomarkers, such as homocysteine, C-reactive protein and interleukin-6, have also been 
associated with cognitive decline13-15; however, previous research has also not focused on the 
very old.  
Identifying individuals at the highest risk of dementia is important for developing targeted 
intervention strategies for the primary prevention of dementia. Determining risk of cognitive 
decline and dementia in dementia-free, cognitively healthy individuals is difficult due to the 
numerous risk factors that have been associated with dementia and individual variability as 
different populations, such as different age groups, may be differently affected by certain risk 
factors. Several dementia risk prediction models have been proposed and investigated in 
population-based longitudinal studies. Examples of risk prediction models for dementia 
include the Australian National University-Alzheimer’s Disease Risk Index (ANU-ADRI), 
the CAIDE model and the Brief Dementia Screening Indicator. Further, the late-life dementia 
risk index was developed in an older population (mean age 76 years). Factors included in 
current dementia risk prediction models are wide-ranging and a recent systematic review 
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concluded that the current models available were not adequate for discriminating those who 
later developed dementia from those who did not develop dementia.16 
Studying the very old presents a unique opportunity to identify factors that are still associated 
with cognitive impairment at the extreme end of ageing, and could be potential targets for 
intervention to maintain cognitive performance. Predicting what impacts cognitive health 
may also have implications regarding impact on healthy life expectancy.17   
The objectives of this study were to determine if there was a prospective association between 
the FSRP,18 the CAIDE risk model3 or oxi-inflammatory load (a sum score of three different 
biomarkers: homocysteine, interleukin-6 and C-reactive protein) with cognitive function in 
very old individuals. Further, we examined whether combining the oxi-inflammatory load 
with the risk scores could affect the association with cognitive function. We used, population-
based data from three of the largest cohort studies in this age group from different regions of 
the world including: the Newcastle 85+ Study (UK), the Leiden 85-plus Study (Netherlands) 
and The Life and Living in Advanced Age: A Cohort Study in New Zealand (LiLACS NZ) 
Study. 
 
METHODS 
All of the datasets used in this study are from longitudinal populations-based studies of health 
and ageing in the very old. 
Newcastle 85+ Study  
All adults born in 1921 who were permanently registered with a participating general practice 
in Newcastle upon Tyne and North Tyneside (North-East England) were invited to 
participate.19, 20 A trained research nurse administered a multidimensional health assessment 
in the participant’s usual place of residence. In total, of 1453 eligible people who were 
invited to participate, 845 had baseline data for both the detailed multidimensional health 
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assessment and general practice record review. For all analyses those with a history of stroke 
or dementia were excluded, in line with previous studies examining associations between the 
Framingham stroke risk profile and cognitive function.21-23 616 participants had complete 
clinical and laboratory data and no previous history of stroke or dementia at baseline. Follow-
up assessments took place at 18, 36 and 60 months from baseline.24  
Leiden 85-plus Study  
Of the 705 residents of Leiden who turned 85 between September 1st 1997 and September 1st 
1999 and who were eligible to participate, 599 responded and participated in the study.25 444 
had complete clinical and laboratory data at baseline and no previous history of stroke or 
dementia at baseline and were included in this analysis. Participants were visited at their 
usual place of residence for a detailed health assessment and their medical records from their 
primary care physician were also reviewed. There were five follow-up assessments which 
took place annually.  
LiLACS NZ Study 
The cohort was derived from two separate populations including Māori (indigenous people in 
NZ) and non-Māori.26 This study only includes the non-Māori cohort aged 85 at baseline to 
allow comparison with the other included cohorts. Individuals born between January 1st and 
December 31st 1925 and who resided within the Lakes or Bay of Plenty District Health Board 
areas when the study enrolment was completed in 2010 were recruited. Of the 870 eligible 
non-Māori individuals whom were identified, 516 enrolled in the study.27 396 had complete 
clinical and laboratory data at baseline and no previous history of stroke or dementia at 
baseline and were included in this analysis. Participants were given the choice to meet at their 
usual place of residence or at another site for a structured face-to-face standardised 
questionnaire, a detailed health assessment and a review of general practice medical records. 
There were three follow-up assessments that took place annually. 
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Assessment of the risk prediction models 
The FSRP and the CAIDE models were determined in each study using baseline data. 
Supplementary Table 1 shows the variables included in each model and their measurement. 
All variables, with the exception of education and physical activity, were measured similarly 
across the cohorts. APOE4 was not available for the LiLACS NZ dataset. For analysis, FSRP 
and CAIDE scores were divided into study-specific tertiles to create low, intermediate and 
high-risk groups, with the low-risk group used as the reference category.11, 28 
Biomarkers and Oxi-inflammatory load  
Three biomarkers previously shown to be associated with cardiovascular diseases were 
selected from the blood results, including two inflammatory biomarkers (i.e., C-reactive 
protein (CRP) and interleukin-6) and one biomarker for oxidative stress (i.e., homocysteine).4 
Details of the biomarker assays in each study can be found in the supplementary material. As 
the distribution of the biomarkers was skewed the data were log transformed. A fixed value 
of 0.1 was added to each data point including zero values to calculate the logarithmic value. 
In order to determine the combined effect of all three biomarkers a cumulative score of the 
standardised z-scores for each log transformed biomarker value was created, this will be 
referred to as a participant’s “oxi-inflammatory load”. Homocysteine was not available for 
the LiLACS NZ dataset and so the cumulative score could not be calculated in this cohort. 
As in previous analyses, the biomarkers and the oxi-inflammatory load scores were grouped 
into deciles and participants were allocated to one of three groups: <10th percentile, 10th-90th 
percentile or >90th percentile and the middle category was used as the reference.29 A 
sensitivity analysis grouping the oxi-inflammatory load scores into three tertile groups (with 
the middle category used as the reference) was also conducted. 
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To examine whether the oxi-inflammatory load scores could enhance the prediction of 
cognitive impairment of the FSRP or the CAIDE scores, further analyses were run by adding 
points to the CAIDE or FSRP scores based on the oxi-inflammatory load values of the 
participants. 6 points were added to the FSRP or CAIDE score for the highest tertile for the 
oxi-inflammatory load scores, 3 points were added for the middle tertile and 0 points were 
added for the highest tertile. 
Cognitive assessment 
Global cognitive function was assessed in all three cohorts using the standard Mini-Mental 
State Examination (MMSE©), with scores ranging from 0 to 30.30 The MMSE© was 
conducted at baseline, 36 months and 60 months in the Newcastle 85+ Study, at baseline and 
annually for five years in the Leiden 85-plus Study, and at baseline and annually for three 
years in the LiLACS NZ Study. For the MMSE©, cognitive impairment at baseline and 
incident cognitive impairment at each follow-up was defined using a cut off score of ≤25 
points. 
Domain specific cognitive functions including attention, information processing and episodic 
verbal recognition memory were assessed in the Newcastle 85+ Study using the Cognitive 
Drug Research (CDR) System. Details of the cognitive assessments in the Newcastle 85+ 
Study have been published elsewhere31. The CDR System was conducted at baseline, 18 
months and 36 months.   
In the Leiden 85-plus Study, speed was measured using the Letter Digit Coding Test. 
Attention was measured using the Stroop test part 3. Memory was measured using the 12 
word learning test. These tests were administered at baseline and annually for five years. 
There were no domain-specific tests completed in the LiLACS NZ Study. 
Statistical analysis 
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Cox proportional hazards models were run to determine whether the FSRP and CAIDE 
scores or the oxi-inflammatory load were associated with the occurrence of impairments in 
global or domain specific cognitive function (dichotomised variables) over the follow-up 
period in each study. Tests of the proportional hazards assumption were run for each model 
and were not violated. Biomarker models were adjusted for potential confounding factors 
including sex, years of education, current alcohol consumption and smoking status.  
Following this, a meta-analysis of the highest HR category was conducted to estimate the 
pooled effects of the FSRP, CAIDE and oxi-inflammatory load scores on prospective risk of 
impaired global cognitive function (i.e., MMSE© scores). HR and 95% confidence intervals 
(95%CI) for each study were entered into the models. Statistical heterogeneity was assessed 
using the I2 and the Q tests and a P<.10 was chosen as a cut-off for heterogeneity.32 A fixed-
effect model was applied as a result of the lack of heterogeneity (Q test, P>.10) and Forest 
plots were generated for the FSRP, CAIDE and oxi-inflammatory load scores. 
Comprehensive Meta-Analysis 2 software (Biostat, Engelwood, New Jersey) was used to 
conduct the analysis.  
Linear mixed models were used to examine change in the continuous test scores for each 
cognitive measure. Cognitive test scores that were positively skewed (i.e. PoA, SRT, Stroop 
Test Part 3) were logarithmically transformed, and MMSE© scores (which were negatively 
skewed) were corrected using the following formula NEWX=SQRT(K-X) where K is the 
maximum score. Each model included the risk model or biomarker score (cross-sectional 
effect), time (change in cognitive scores over time) and an interaction term between the risk 
model or biomarker score and time (additional effect of the risk model or biomarker score). 
All data were analysed using Stata v.13.0 (Stata Corp LP, College Station, TX, USA). 
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RESULTS 
After excluding participants with a history of stroke or dementia at baseline the analytical 
sample included 616 participants in the Newcastle 85+, 444 in the Leiden 85-plus and 396 in 
the LiLACS NZ studies. The baseline characteristics of each sample are shown in Table 1. 
The Framingham stroke risk profile 
Global cognitive function 
For the individual studies, the hazard ratios for an increased risk of impaired global cognitive 
function were all above one for the highest FSRP groups (Table 2). Meta-analysis of pooled 
results showed an increased risk of impaired global cognitive function with a higher FSRP 
(MMSE©: HR=1.46, 95%CI: 1.08 to 1.98, P=.01). However, in the linear mixed models the 
associations between the FSRP and global cognitive function (cross-sectional results) or 
global cognitive decline were all P>.05 (Supplementary Table 2). 
Domain specific cognitive function 
Upon examining the specific cognitive domains, which are only available for the Newcastle 
85+ and Leiden 85-plus studies, higher FSRP scores were associated with an increased risk of 
impaired speed for the Newcastle 85+ Study (SRT: HR=1.42; 95%CI: 1.06 to 1.91, P=.02) 
(Table 4). In the linear mixed models the FSRP was cross-sectionally associated with speed 
scores for the Leiden 85-plus Study only (LDCT: (Β (SE)=-2.19 (0.913), P=.02) (Table 5). 
The CAIDE model  
Global cognitive function 
Higher CAIDE scores were associated with an increased risk of impaired global cognitive 
function in the meta-analysis of pooled MMSE© results (HR=1.46, 95%CI: 1.05 to 2.02, 
P=.02). For the linear mixed model results, the CAIDE model was cross-sectionally 
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associated with global cognitive function in the Leiden 85-plus Study (Β (SE)=0.493 (0.112), 
P<.001) and the LiLACS NZ Study (Β (SE)=0.348 (0.109), P=.001). 
Domain specific cognitive function 
The CAIDE model was not longitudinally associated with any of the domain specific 
cognitive test results for the Newcastle 85+ or Leiden 85-plus studies for the Cox 
proportional hazard models or the linear mixed models. However, the linear mixed models 
showed the CAIDE model was cross-sectionally associated with speed, attention and memory 
scores for the Leiden 85-plus Study. 
Oxi-inflammatory load  
Global cognitive function 
A higher oxi-inflammatory load was associated with incident global cognitive impairment in 
the meta-analysis of pooled results (Newcastle 85+ Study and Leiden 85-plus Study only: 
HR=1.73, 95%CI: 1.04 to 2.88, P=.04) (Figure 1). In the linear mixed models, the oxi-
inflammatory load was not longitudinally associated with global cognitive decline, but a 
cross-sectional association was observed between a higher oxi-inflammatory load and poorer 
global cognitive function scores at baseline (Β (SE)=0.320 (0.127), P=.01) in the Leiden 85-
plus Study.   
Domain specific cognitive function 
A higher oxi-inflammatory load was associated with an increased risk of incident impairment 
of attention in both the Newcastle 85+ (HR=1.58; 95%CI: 1.05 to 2.36, P=.03), and Leiden 
85-plus studies (HR=2.18; 95%CI: 1.27 to 3.74, P=.01) (Table 3). Further, a higher oxi-
inflammatory load was also associated with an increased risk of impairment of speed in the 
Newcastle 85+ Study (HR=1.85; 95%CI: 1.24 to 2.75, P=.003), but this association was not 
observed in the Leiden study. In the linear mixed models, a higher oxi-inflammatory load was 
not longitudinally associated with any of the domain specific cognitive test results for the 
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Newcastle 85+ or Leiden 85-plus studies. However, the linear mixed models showed a higher 
oxi-inflammatory load was cross-sectionally associated with better attention scores for the 
Newcastle 85+ Study (Β (SE)=0.058 (0.028), P=.04) (Table 4).  
Adding the oxi-inflammatory load to the FSRP and CAIDE model 
In order to determine if the oxi-inflammatory load could be used to improve the prediction of 
the FSRP or CAIDE models we added the oxi-inflammatory load scores to the FSRP and 
CAIDE scores as described in the methods. In the meta-analysis of pooled results (Newcastle 
85+ Study and Leiden 85+ Study only), adding the oxi-inflammatory load scores improved 
the prediction of both the CAIDE (HR for CAIDE and oxi-inflammatory load=1.93; 95% CI: 
1.39 to 2.67, P<.001 and FSRP scores (HR for FSRP and oxi-inflammatory load=1.65; 95% 
CI: 1.17 to 2.33, P<.001). 
Sensitivity Analysis 
The Leiden 85-plus dataset did not have years of education, but the education measure was 
based on the education system in the Netherlands, therefore we re-ran the analysis of the 
CAIDE score and excluded education from its calculation in order to examine if differences 
in the operationalization of education was the reason for the discrepant results between the 
studies. When education was excluded the result changed and the CAIDE score was no 
longer associated with global cognitive impairment (Leiden 85-plus: HR for the highest risk 
tertile compared to the lowest=1.25, 95%CI: 0.81 to 1.92, P=.30).  
Analyses for the Cox proportional hazard models were repeated using tertiles for the oxi-
inflammatory load (middle category as reference) (MMSE©: HR=1.36, 95%CI: 0.96 to 1.92, 
P=.07).   
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DISCUSSION 
In three prospective studies of individuals aged 85 years, free of stroke or dementia at 
baseline, from the UK, the Netherlands and New Zealand, we found that higher FSRP and 
CAIDE risk scores or a higher oxi-inflammatory load, derived from a cumulative score of 
three cardiovascular biomarkers, were associated with incident global impairment. Further, 
incorporating the oxi-inflammatory load scores in to the FSRP or CAIDE model improved 
the ability of the risk models to predict incident global cognitive impairment. However, this 
could only be determined using the Newcastle 85+ Study and the Leiden 85-plus Study data 
as the LiLACS NZ Study does not have homocysteine measures needed to determine the oxi-
inflammatory load. 
Several longitudinal studies have found both the Framingham and the CAIDE risk models to 
(for a review of studies see).21 When investigating specific cognitive domains, the results 
have however been inconsistent with regards to which cognitive domains may be affected by 
higher cardiovascular risk.5-8, 11, 33 Yet, the majority of studies have focused on the midlife 
and younger old populations, and no study has previously looked at the association between 
cardiovascular risk models and cognitive function in the very old.  
Studies in relatively younger populations have found that homocysteine, interleukin-6 and C-
reactive protein predict cognitive decline.13-15 Previous findings in the Newcastle 85+ Study 
have shown cross-sectional associations between these biomarkers and global cognitive 
impairment measured using the MMSE©.29 Similarly, previous findings in the Leiden 85-plus 
Study have also shown cross-sectional associations between homocysteine and cognitive 
impairment, but this association was not found with rate of cognitive decline.34 
In this study, higher levels of biomarkers for oxidative stress and inflammation were 
longitudinally associated with an increased risk of developing global and domain specific 
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cognitive (speed and attention) impairment. Biomarkers of cardiovascular risk may be useful 
for identifying those at risk of future cognitive impairment as oxidative stress and 
inflammation are also implicated in the pathophysiology of dementia. It is widely accepted 
that increasing levels of oxidative stress and impaired cellular functions linked to abnormal 
protein accumulation and modification of molecular structures may have direct effects on 
neuronal structure and integrity, affecting cognitive function.35 Further, inflammation is 
thought to be a key factor in neurodegeneration, contributing to the development of some of 
the classic hallmarks of Alzheimer’s pathology such as amyloid-beta plaques.36 These 
findings have been formalised in the theory of inflammaging as a critical factor in the 
pathogenesis of age-related chronic cardiovascular and neurodegenerative diseases.37, 38  
Current dementia risk prediction models are not sufficient for detecting those at greatest risk 
of developing cognitive impairment or dementia16. Factors included in current dementia risk 
prediction models include demographic factors (e.g., age, sex, ethnicity), subjective cognitive 
complaints, functioning (as measured by Activities of daily living (ADLs) scales), 
neuropsychological test scores, health related measures (e.g., history of cardiovascular 
disease, body mass index), lifestyle measures (e.g., smoking status, alcohol intake), dietary 
related factors (e.g., folic acid and fish intake), magnetic resonance imaging (MRI) results 
(e.g., white matter disease) and others (e.g., family history of dementia). The best models 
were described as those which incorporated a diverse range of risk factors into the models, 
but it is most likely that there will not be one model which is suitable for all populations and 
different dementia risk models may need to be developed for different populations (e.g., 
based on age group)39. To date, no such dementia risk model has been validated in a very old 
population. Development of a highly accurate model for discriminating those at high-risk of 
future dementia from those at medium and low-risk would be needed before screening the 
older population for future risk of dementia in primary care practice could become a 
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possibility. Incorporation of the biomarkers investigated in this study with the classical 
cardiovascular risk factors of the FSRP or CAIDE models may be useful to investigate when 
developing a dementia risk prediction model for the very old. 
There are both strengths and limitations to this study. The Newcastle 85+, Leiden 85-plus and 
LiLACS NZ cohorts are prospective longitudinal cohort studies of the very old and this is the 
first study that has aggregated data from all three cohorts.  
There are some limitations, the LiLACS NZ Study did not have homocysteine levels needed 
to create the oxi-inflammatory load and therefore, the findings for the oxi-inflammatory load 
are based on the Newcastle 85+ and Leiden 85-plus studies only.  
Results were not always consistent across the studies and discrepancies in results between 
studies may be due to: 1) differences in the assays used to determine C-reactive protein and 
interleukin-6 across the two studies, since the Leiden 85-plus Study used less sensitive assays 
which led to the attribution of values of zero for results lower than the limit of detection 
(number of zero values: C-reactive protein=82, interleukin-6=119), 2) differences in the 
cohorts themselves, for instance, education levels varied widely, the Leiden Study did not 
have years of education needed to correctly determine the CAIDE scores, the LiLACS Study 
did not have APOE4 required for the CAIDE model, differences in the cognitive tests used to 
asses domain-specific cognitive function and the smaller sample size of the Leiden 85-plus 
Study and LiLACS NZ Study, 3) a cohort effect related to differences in birth year between 
cohorts: [1913-1915 (Leiden 85-plus Study), 1921 (Newcastle 85+ Study) and 1925 
(LiLACS NZ Study)]. 
Further research in very old age groups is needed to gain a full understanding of the 
association between the Framingham models, the CAIDE models or cardiovascular 
biomarkers and cognitive decline. In particular with respect to which cognitive domains may 
be most likely to be affected.  
17 
 
 
 
There is currently no recommended tool for identifying those at risk of developing cognitive 
impairment or dementia in the very old population.16 Combining the oxi-inflammatory load 
with the FSRP or the CAIDE model may further improve the ability of these models to 
predict cognitive changes. Biomarkers would be relatively easy to measure in a clinical 
setting and could potentially provide clinicians with an overview of a patient’s cardiovascular 
health in addition to their future risk for cognitive impairment. Intervention strategies to 
reduce the oxi-inflammatory load could potentially target both improvements in 
cardiovascular health and cognitive function. 
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FIGURE LEGENDS 
Figure 1: Forest plots to show the pooled risk for impaired global cognitive function, 
measured by MMSE© in all three cohorts, associated with higher Cardiovascular risk factors, 
Aging and Dementia model (CAIDE) and Framingham stroke risk profile (FSRP) risk scores 
and oxi-inflammatory load. 
 
  
23 
 
 
 
Table 1. Baseline characteristics of participants in the Newcastle 85+, Leiden 85-plus Study 
and the LiLACS NZ studies used in this analysis (excluding those with dementia or stroke at 
baseline). 
Characteristic Study 
Risk model components Newcastle 85+ study  
(n=616) 
Leiden 85-plus Study 
(n=444) 
LiLACS NZ  
(n=396) 
Male, % 39.9 34.6 48.0 
Systolic blood pressure (mmHg), mean (SD) 151.4 (23.5) 155.2 (18.7) 151.6 (22.8) 
Total cholesterol (mg/dl), mean (SD) 192.0 (48.0) 220.8 (43.7) 199.8 (41.8) 
Body mass index (kg/m²), mean (SD) 24.5 (4.4) 27.1 (4.5) 26.5 (4.3) 
Blood pressure lowering drugs, % 70.8 43.9 60.4 
Current smoker, % 5.3 16.0 5.1 
Diabetes, % 18.2 13.9 13.1 
Atrial Fibrillation, % 14.2 9.1 12.2 
History of CVD, % 38.7 33.6 42.2 
Physical activity, active, % 44.0 29.0 37.7 
Education <10 years or low category, % 64.0 72.0  27.0 
Risk models    
FSRP score (all), mean (SD) 19.5 (3.6), range 11-33 19.1 (3.8), range 10-33 18.9 (3.7), range 10-31 
Low, % 42.2  34.3 33.7 
Medium, % 25.0 34.8 36.2 
High, % 32.5 30.9 30.1 
CAIDE score (all), mean (SD) 8.5 (1.9), range 4-13 10.2 (1.7), range 4-15 7.9 (1.8), range 4-13 
Low, % 48.7 59.3 48.4 
Medium, % 24.3 16.8 34.2 
High, % 27.0 23.9 17.4 
Biomarkers    
Homocysteine (µmol/L), median (IQR) 16.7 (7.9) 12.5 (5.5) - 
Interleukin 6 (ng/mL), median (IQR) 19.7 (20.6) 10.0 (53.0) 2.3 (1.0) 
C-reactive protein (mg/L), median (IQR) 2.5 (4.9) 3.0 (7.0) 2.9 (4.2) 
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Oxi-Inflammatory Load, mean (SD) -0.1 (2.0) -0.1 (2.0) 0.1 (1.7) 
Cognitive function scores    
Global cognitive function, median (IQR) 27.3 (2.8) 27.0 (4.0) 27.0 (3.2) 
Memory, median (IQR) 0.6 (0.2) 0.2 (1.8) - 
Attention, median (IQR) 1521.8 (290.3) 74.8 (37.9) - 
Speed, median (IQR) 417.6 (149.6) 16.0 (9.0) - 
 
 
 
 
  
The CAIDE score for LiLACS NZ study does not include ApoE4. Oxi-inflammatory load for LiLACS NZ study is 
only based on interleukin-6 and C-reactive protein. Education for the Leiden 85-plus Study is not based on years of 
education, but is determined by the categorizations of education used in the Leiden 85-plus Study. Abbreviations: 
CAIDE, Cardiovascular risk factors, Aging and Dementia model; CVD, cardiovascular disease; FSRP, 
Framingham stroke risk profile; IQR, interquartile range; SD, standard deviation. Newcastle 85+: Memory was 
measured using the sensitivity index for recognition ability (SI), attention was measured using power of attention 
(PoA) and speed was measured using simple reaction time (SRT), all part of the Cognitive Drug Research (CDR) 
computerised assessment system. Leiden 85-plus Study: Memory was measured using the Word-Learning Test, 
Immediate and Delayed Recall (based on sum of z scores), attention was measured using the Stroop Test Part 3 and 
speed was measured using the Letter Digit Coding Test. Numbers exclude people with dementia or stroke at 
baseline. 
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Table 2. Cox proportional hazard model results (HR and 95%CI) of the association between the FSRP, the CAIDE models, oxi-inflammatory 
load and incident global cognitive impairment after follow-up for the Newcastle 85+ study, Leiden 85-plus Study and LiLACS NZ cohorts.  
 Meta-analysis  Newcastle 85+ study  Leiden 85-plus Study  LiLACS NZ Study  
 HR (95% CI)  P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
Global cognitive function         
FSRP   
Low 1.0  1.0  1.0  1.0  
Medium   0.95 (0.57, 1.59) .85 0.99 (0.65, 1.53) .97 1.56 (0.64, 3.77) .33 
High 1.46 (1.08, 1.98) .01 1.15 (0.71, 1.86) .56 1.44 (0.93, 2.22) .10 3.53 (1.44, 8.63) .01 
CAIDE         
Low 1.0  1.0  1.0  1.0  
Medium   0.83 (1.50, 0.46) .54 1.84 (1.14, 2.96) .01 2.43 (1.13, 5.22) .02 
High 1.53 (1.09, 2.14) .01 1.14 (0.64, 2.03) .65 1.64 (1.04, 2.58) .03 2.87 (0.97, 8.47) .06 
Oxi-inflammatory load         
Low 1.0  1.02 (0.53, 1.96) .95 0.65 (0.31, 1.35) .25 -  
Medium   1.0   1.0  -  
High 1.73 (1.04, 2.98) .04 2.13 (1.08, 4.20) .03 1.32 (0.61, 2.86) .48 -  
CAIDE + oxi-inflammatory load        
Low 1.0  1.0  1.0  -  
Medium   1.38 (0.77, 2.46) .28 1.28 (0.83, 1.97) 0.26 -  
High 1.93 (1.39, 2.67) <.001 1.96 (1.27, 3.42) .02 1.89 (1.18, 3.02) .008 -  
FSRP + oxi-inflammatory load        
Low 1.0  1.0  1.0  -  
Medium   1.20 (0.75, 1.93) .45 1.36 (0.88, 2.09) .17 -  
High 1.65 (1.17, 2.33) <.001 1.59 (0.94, 2.69) .08 1.70 (1.08, 2.68) .02 -  
 
Abbreviations: CAIDE, Cardiovascular risk factors, Aging and Dementia model; CVD, cardiovascular disease; FSRP, Framingham stroke risk profile. Global 
cognitive function measured by the Mini-Mental State Examination (MMSE) in all studies. Oxi-inflammatory load represents a sum score of the three 
biomarkers: standardised z-scores for each log transformed biomarker were calculated and the sums of these scores were then determined to create an oxi-
inflammatory load. Categories based on tertiles for the FSRP and CAIDE models and for the oxi-inflammatory load: low represents <10th percentile, middle 
represents 10th-90th percentile and high represents >90th percentile. Impairment is ≤25 points on the MMSE for global cognitive function. Oxi-inflammatory load 
models adjusted for sex, years of education, current alcohol consumption and smoking status. 
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Table 3. Linear mixed model results (β (SE) P-value) of the association between the FSRP, the CAIDE model, oxi-inflammatory load and 
cognitive decline after follow-up for the Newcastle 85+ Study, Leiden 85-plus Study and LiLACS NZ cohorts 
  Newcastle 85+ Study   Leiden 85-plus Study   LiLACS NZ Study  
  Β (SE) P-value   Β (SE) P-value   Β (SE) P-value  
 Cross-sectional  Change over time Change due to the 
risk model 
Cross-sectional  Change over time Change due to the 
risk model 
Cross-sectional  Change over time Change due to the 
risk model 
Global cognitive function        
FSRP          
Low 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Medium -0.026 (0.098) 0.32 0.109 (0.019) <0.001 0.011 (0.030) 0.71 -0.033 (0.111) 0.77 0.129 (0.015) <0.001 -0.031 (0.021) 0.15 0.029 (0.091) 0.75 0.018 (0.029) 0.54 -0.069 (0.041) 0.09 
High -0.083 (0.093) 0.37 0.109 (0.019) <0.001 0.024 (0.031) 0.43 0.159 (0.115) 0.17 0.129 (0.015) <0.001 -0.015 (0.023) 0.53 -0.052 (0.097) 0.59 0.018 (0.029) 0.54 0.043 (0.046) 0.36 
CAIDE          
Low 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Medium 0.071 (0.105) 0.50 0.109 (0.021) <0.001 -0.018 (0.035) 0.60 0.126 (0.128) 0.33 0.102 (0.012) <0.001 0.057 (0.025) 0.02 0.053 (0.088) 0.54 0.008 (0.026) 0.76 -0.011 (0.040) 0.99 
High 0.123 (0.103) 0.23 0.109 (0.021) <0.001 0.053 (0.037) 0.15 0.493 (0.112) <0.001 0.102 (0.012) <0.001 0.001 (0.022) 0.99 0.348 (0.109) 0.001 0.008 (0.026) 0.76 -0.032 (0.054) 0.54 
Oxi-inflammatory load         
Low -0.148 (0.138) 0.28 0.118 (0.014) <0.001 0.022 (0.041) 0.60 0.060 (0.147) 0.68 0.118 (0.010) <0.001 -0.023 (0.031) 0.45 - - - 
Medium 0.0 0.0 0.0 0.0 0.0 0.0    
High 0.20 (0.121) 0.10 0.118 (0.014) <0.001 -0.018 (0.047) 0.70 0.320 (0.127) 0.01 0.118 (0.010) <0.001 0.007 (0.033) 0.83    
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Abbreviations: CAIDE, Cardiovascular risk factors, Aging and Dementia model; CVD, cardiovascular disease; FSRP, Framingham stroke risk profile. 
Global cognitive function measured by the Mini-Mental State Examination in all studies. Cognitive tests that were not normally distributed were 
transformed. Oxi-inflammatory load represents a sum score of the three biomarkers: standardised z-scores for each log transformed biomarker were 
calculated and the sums of these scores were then determined to create an oxi-inflammatory load. Categories based on tertiles for the FSRP and CAIDE 
models and for the oxi-inflammatory load: low represents <10th percentile, middle represents 10th-90th percentile and high represents >90th percentile. For 
the non-MMSE measurements, impairment was defined as a score 1.5 standard deviations below (or above where higher scores indicate worse 
performance) the mean score. Where scores were not normally distributed this was calculated as the 93rd percentile for scores where higher numbers 
reflect worse cognitive function, and the 7th percentile for scores where lower numbers reflect worse cognitive function. Oxi-inflammatory load models 
adjusted for sex, years of education, current alcohol consumption and smoking status. 
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Table 4. Cox proportional hazard model results (HR and 95%CI) of the association between 
the FSRP and the CAIDE models, oxi-inflammatory load and incident domain-specific 
cognitive impairment after follow-up for the Newcastle 85+ study and Leiden 85-plus Study. 
 
 Newcastle 85+ study  Leiden 85-plus Study  
 HR (95% CI) P HR (95% CI) P 
Attention     
FSRP 
Low 1.0  1.0  
Medium 0.99 (0.71, 1.38) 0.97 0.94 (0.67, 1.30) 0.69 
High 1.27 (0.95, 1.70) 0.11 1.31 (0.94, 1.81) 0.11 
CAIDE     
Low 1.0  1.0  
Medium 0.89 (0.61, 1.28) 0.53 1.57 (1.11, 2.23) 0.01 
High 1.25 (0.89, 1.76) 0.20 1.16 (0.82, 1.63) 0.40 
Oxi-inflammatory load     
Low 0.56 (0.33, 0.94) 0.01 0.80 (0.45, 1.43) 0.45 
Medium 1.0  1.0  
High 1.58 (1.05, 2.36) 0.03 2.18 (1.27, 3.74) 0.01 
Memory     
FSRP 
Low 1.0  1.0  
Medium 0.77 (0.40, 1.50) 0.45 1.22 (0.60, 2.46) 0.59 
High 0.73 (0.39, 1.36) 0.32 1.14 (0.57, 2.26) 0.72 
CAIDE     
Low 1.0  1.0  
Medium 1.01 (0.49, 2.17) 0.97 1.02 (0.40, 2.60) 0.97 
High 1.17 (0.56, 2.44) 0.68 0.86 (0.46, 1.63) 0.65 
Oxi-inflammatory load     
Low 0.79 (0.34, 1.85) 0.59 0.65 (0.22, 1.90) 0.43 
Medium 1.0  1.0  
High 1.11 (0.44, 2.80) 0.83 3.87 (0.84, 17.9) 0.08 
Speed     
FSRP 
Low 1.0  1.0  
Medium 1.11 (0.79, 1.55) 0.54 1.00 (0.60, 1.68) 0.98 
High 1.42 (1.06, 1.91) 0.02 0.98 (0.55, 1.75) 0.96 
CAIDE     
Low 1.0  1.0  
Medium 0.83 (0.57, 1.21) 0.34 1.42 (0.75, 2.68) 0.28 
High 1.18 (0.83, 1.68) 0.35 0.97 (0.54, 1.72) 0.91 
Oxi-inflammatory load     
Low 0.65 (0.39, 1.08) 0.10 0.78 (0.30, 2.01) 0.61 
Medium 1.0  1.0  
High 1.85 (1.24, 2.75) 0.003 1.85 (0.43, 7.87) 0.41 
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Abbreviations: CAIDE, Cardiovascular risk factors, Aging and Dementia model; CVD, cardiovascular disease; FSRP, Framingham 
stroke risk profile. Oxi-inflammatory load represents a sum score of the three biomarkers: standardised z-scores for each log transformed 
biomarker were calculated and the sums of these scores were then determined to create an oxi-inflammatory load. Newcastle 85+: 
Memory was measured using the sensitivity index for recognition ability (SI), attention was measured using power of attention (PoA) and 
speed was measured using simple reaction time (SRT), all part of the Cognitive Drug Research (CDR) computerised assessment system. 
Leiden 85-plus Study: Memory was measured using the Word-Learning Test, Immediate and Delayed Recall, attention was measured 
using the Stroop Test Part 3 and speed was measured using the Letter Digit Coding Test. Categories based on tertiles for the FSRP and 
CAIDE models and for the oxi-inflammatory load: low represents <10th percentile, middle represents 10th-90th percentile and high 
represents >90th percentile. For the non-MMSE measurements, impairment was defined as a score 1.5 standard deviations below (or 
above where higher scores indicate worse performance) the mean score. Where scores were not normally distributed this was calculated 
as the 93rd percentile for scores where higher numbers reflect worse cognitive function, and the 7th percentile for scores where lower 
numbers reflect worse cognitive function. Oxi-inflammatory load models adjusted for sex, years of education, current alcohol 
consumption and smoking status. 
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Oxi-inflammatory load represents a sum score of the three biomarkers: standardised z-scores for each log 
transformed biomarker were calculated and the sums of these scores were then determined to create an oxi-
inflammatory load. The LiLACS NZ study did not measure homocysteine and therefore was not included in 
the oxi-inflammatory load meta-analysis. 
 
